2022
Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis
Chhoda A, Singh S, Sheth AH, Grimshaw AA, Gunderson C, Sharma P, Kunstman JW, Sharma A, Ahuja N, Gonda TA, Farrell JJ. Benefit of Extended Surveillance of Low-Risk Pancreatic Cysts After 5-Year Stability: A Systematic Review and Meta-Analysis. Clinical Gastroenterology And Hepatology 2022, 21: 1430-1446. PMID: 35568304, DOI: 10.1016/j.cgh.2022.04.025.Peer-Reviewed Original ResearchMeSH KeywordsCarcinoma, Pancreatic DuctalHumansPancreatic CystPancreatic DuctsPancreatic Intraductal NeoplasmsPancreatic NeoplasmsRetrospective StudiesConceptsDisease-specific mortalityAdvanced neoplasiaBD-IPMNsExtended surveillancePooled incidenceWorrisome featuresSystematic reviewIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPapillary mucinous neoplasmHigh-quality studiesRandom-effects modelWarrants further investigationWeb of ScienceNeoplasia incidenceWarrants further explorationSurvival benefitCochrane LibraryMucinous neoplasmsPancreatic cancerPancreatic cystsSurveillance periodEligible studiesOvid MEDLINELower incidence
2020
Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival
Heller DR, Nicolson NG, Ahuja N, Khan S, Kunstman JW. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surgery 2020, 155: e195047. PMID: 31800002, PMCID: PMC6902102, DOI: 10.1001/jamasurg.2019.5047.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaNational Cancer DatabaseWhite patientsBlack patientsAdvanced diseaseOverall survivalClinical parametersDisease stageCancer DatabaseSurgical proceduresMultivariable Cox proportional hazards regression modelingTreatment inequitiesCox proportional hazards regression modelingPancreatic ductal adenocarcinoma (PDAC) survivalUnadjusted median overall survivalYounger ageProportional hazards regression modelingMedian overall survivalModest survival advantageStage II diseaseNew cancer diagnosesLess chemotherapyResectable cancerCohort studyPrimary outcome
2018
A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent
Thakar M, Hu Y, Morreale M, Lerner L, Lin W, Sen R, Cai Y, Karunasena E, Thakar M, Saggi S, Keer H, Ahuja N. A novel epigenetic modulating agent sensitizes pancreatic cells to a chemotherapy agent. PLOS ONE 2018, 13: e0199130. PMID: 29927979, PMCID: PMC6013229, DOI: 10.1371/journal.pone.0199130.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaDNA methyltransferase 1Chemotherapeutic agent irinotecanEpigenetic modulating agentsPDAC cell linesCell viabilityMechanism of actionSystemic chemotherapyCancer mortalityChemotherapy responseDuctal adenocarcinomaChemotherapy agentsEpigenetic sensitizationModulating agentsGuadecitabineAdditional studiesPancreatic cellsSerial concentrationsRest periodCell linesNanomolar concentrationsImproved responseEpigenetic modulatorsSensitizationMethyltransferase 1
2017
Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions
Poruk KE, Valero V, He J, Ahuja N, Cameron JL, Weiss MJ, Lennon AM, Goggins M, Wood LD, Wolfgang CL. Circulating Epithelial Cells in Intraductal Papillary Mucinous Neoplasms and Cystic Pancreatic Lesions. Pancreas 2017, 46: 943-947. PMID: 28697136, DOI: 10.1097/mpa.0000000000000869.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPapillary mucinous neoplasmBlood of patientsEpithelial cellsMucinous neoplasmsPancreatic lesionsAbsence of malignancyBenign pancreatic lesionsCystic pancreatic lesionsNineteen patientsPancreatic resectionPeripheral bloodPancreatic cystsISET methodPatientsPancreas-specific markersResectionMalignancyDysplasiaBloodNeoplasmsPancreatic sourceLow gradeLesionsNeutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas
Gemenetzis G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, Lennon AM, Wood LD, Hruban RH, Zheng L, Zaheer A, Fishman EK, Ahuja N, Cameron JL, Weiss MJ, He J, Wolfgang CL. Neutrophil-to-lymphocyte Ratio is a Predictive Marker for Invasive Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals Of Surgery 2017, 266: 339-345. PMID: 27631774, DOI: 10.1097/sla.0000000000001988.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmPapillary mucinous neoplasmInvasive carcinomaPredictive nomogramLymphocyte ratioMucinous neoplasmsInvasive malignancyPredictive markerMain pancreatic duct dilatationEnhanced solid componentLymphocyte ratio valuesIndependent predictive markerFurther prospective studiesPancreatic duct dilatationInflammatory markersSurgical resectionDuct dilatationNLR valuesOverall survivalProspective studyPancreatic cancerC-indexCarcinomaMultivariate analysisPatients
2015
Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma
Rezaee N, Barbon C, Zaki A, He J, Salman B, Hruban RH, Cameron JL, Herman JM, Ahuja N, Lennon AM, Weiss MJ, Wood LD, Wolfgang CL. Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. Hepato Pancreato Biliary 2015, 18: 236-246. PMID: 27017163, PMCID: PMC4814593, DOI: 10.1016/j.hpb.2015.10.010.Peer-Reviewed Original ResearchMeSH KeywordsAgedCarcinoma, Pancreatic DuctalDatabases, FactualDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateLymphatic MetastasisMaleMiddle AgedNeoplasm GradingNeoplasm InvasivenessNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Second PrimaryPancreatectomyPancreatic NeoplasmsProportional Hazards ModelsRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeConceptsIntraductal papillary mucinous neoplasmHigh-grade dysplasiaPancreatic ductal adenocarcinomaNon-invasive intraductal papillary mucinous neoplasmsIntermediate-grade dysplasiaPapillary mucinous neoplasmRemnant pancreasVascular invasionMucinous neoplasmsDuctal adenocarcinomaInvasive pancreatic ductal adenocarcinomaMedian overall survivalLymph node metastasisRate of progressionSubsequent developmentIntermediate dysplasiaPancreatic resectionOverall survivalNode metastasisPerineural invasionMalignant entitiesRisk factorsPatientsDysplasiaPancreasAGA Guidelines for the Management of Pancreatic Cysts
Lennon AM, Ahuja N, Wolfgang CL. AGA Guidelines for the Management of Pancreatic Cysts. Gastroenterology 2015, 149: 825. PMID: 26231607, DOI: 10.1053/j.gastro.2015.05.062.Peer-Reviewed Original Research
2013
Is It Necessary to Follow Patients after Resection of a Benign Pancreatic Intraductal Papillary Mucinous Neoplasm?
He J, Cameron JL, Ahuja N, Makary MA, Hirose K, Choti MA, Schulick RD, Hruban RH, Pawlik TM, Wolfgang CL. Is It Necessary to Follow Patients after Resection of a Benign Pancreatic Intraductal Papillary Mucinous Neoplasm? Journal Of The American College Of Surgeons 2013, 216: 657-665. PMID: 23395158, PMCID: PMC3963007, DOI: 10.1016/j.jamcollsurg.2012.12.026.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Pancreatic DuctalFemaleFollow-Up StudiesHumansMaleMiddle AgedPancreatectomyPancreatic NeoplasmsRetrospective StudiesRisk AssessmentConceptsIntraductal papillary mucinous neoplasmNoninvasive intraductal papillary mucinous neoplasmsPapillary mucinous neoplasmPancreatic cancerFamily historyMucinous neoplasmsNegative marginsInitial operationPancreatic intraductal papillary mucinous neoplasmsPartial pancreatic resectionMetastatic pancreatic adenocarcinomaInvasive pancreatic cancerRisk of developmentDegree of dysplasiaInitial surgeryMargin statusPancreatic resectionClose surveillanceInvasive adenocarcinomaPancreatic adenocarcinomaResectionPatientsCancerSurgeryAdenocarcinoma
2012
Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts
He J, Edil BH, Cameron JL, Schulick RD, Hruban RH, Herman JM, Zheng L, Iacobuzio-Donahue C, Ahuja N, Pawlik TM, Wolfgang CL. Young Patients Undergoing Resection of Pancreatic Cancer Fare Better than their Older Counterparts. Journal Of Gastrointestinal Surgery 2012, 17: 339-344. PMID: 23184271, PMCID: PMC3600849, DOI: 10.1007/s11605-012-2066-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAgedCarcinoma, Pancreatic DuctalFemaleHumansMaleMiddle AgedPancreatic NeoplasmsRetrospective StudiesSurvival RateConceptsCharlson-Age Comorbidity IndexOlder age groupsDate of surgeryYounger patientsOlder patientsAge groupsMedian agePDAC patientsPancreatic ductal adenocarcinoma patientsPatients Undergoing ResectionMedian overall survivalResectable pancreatic cancerLymph node positivityYoung patient cohortDuctal adenocarcinoma patientsYounger age groupsCurative resectionUndergoing resectionAbdominal painDistal pancreatectomyR0 resectionTotal pancreatectomyUnderwent pancreaticoduodenectomyElderly patientsNode positivity
2008
Retroperitoneal masses with associated human chorionic gonadotropin production: Report of two cases
Duffield AS, Jarrar P, Shum C, Ahuja N, Yeo CJ, Sokoll LJ. Retroperitoneal masses with associated human chorionic gonadotropin production: Report of two cases. Clinica Chimica Acta 2008, 395: 166-169. PMID: 18505680, DOI: 10.1016/j.cca.2008.04.030.Peer-Reviewed Original ResearchConceptsHuman chorionic gonadotropinSerum human chorionic gonadotropinSerum hCG concentrationsRetroperitoneal massHCG concentrationsEpidermoid cystHCG secretionHuman chorionic gonadotropin productionCancer antigen 19Course of diseaseChorionic gonadotropin productionBenign epidermoid cystPancreatic ductal adenocarcinomaPathologic examinationAntigen 19Gonadotropin productionCyst liningMalignant neoplasmsDisease progressionDuctal adenocarcinomaPancreatic adenocarcinomaImmunohistochemical stainingChorionic gonadotropinPatientsCysts